Get the Stockscreener App
16.17
19.86%
2.65
Kalvista Pharmaceuticals Inc stock is traded at $16.17, with a volume of 2.82M.
It is up +19.86% in the last 24 hours and up +50.05% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$13.52
Open:
$13.64
24h Volume:
2.82M
Relative Volume:
2.11
Market Cap:
$820.11M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-4.3821
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+14.93%
1M Performance:
+50.05%
6M Performance:
+21.39%
1Y Performance:
+66.55%
1-Day Range:
$13.37
$16.49
1-Week Range:
$13.28
$16.49
52-Week Range:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
16.23 | 683.39M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.44 | 109.90B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.64 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.01 | 61.42B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
933.35 | 56.36B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.50 | 44.06B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Why pension funds invest in KalVista Pharmaceuticals Inc. (4XC1) stockWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Will KalVista Pharmaceuticals Inc. (4XC1) stock profit from automation waveJuly 2025 Review & Safe Capital Investment Plans - Newser
How KalVista Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Is KalVista Pharmaceuticals Inc. stock a contrarian buyJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Behavioral Patterns of KALV and Institutional Flows - news.stocktradersdaily.com
KalVista Pharma CMO Audhya sells $71k in stock By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Stock (KALV) Opinions on Q3 Revenue Success - Quiver Quantitative
KALV SEC FilingsKalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
KalVista Pharma CFO Piekos sells $60k in shares By Investing.com - Investing.com Canada
KalVista Pharma exec Yea sells $58k in shares By Investing.com - Investing.com Nigeria
KalVista Pharma CMO Audhya sells $71k in stock - Investing.com
KalVista Pharma exec Yea sells $58k in shares - Investing.com
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Officer Audhya Acquires 5,954 Of KalVista Pharmaceuticals Inc [KALV] - TradingView
KalVista Pharmaceuticals, Inc. (KALV) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is KalVista Pharmaceuticals Inc. stock positioned well for digital economyGap Down & High Conviction Buy Zone Picks - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedQuarterly Earnings Summary & AI Powered Buy and Sell Recommendations - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.July 2025 Trends & Consistent Profit Trade Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesQuarterly Portfolio Review & Consistent Growth Equity Picks - newser.com
Citizens reiterates Market Outperform rating on Kalvista stock at $28 target - Investing.com Canada
How to manage a losing position in KalVista Pharmaceuticals Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycle2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - Insider Monkey
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates - MSN
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockJuly 2025 Review & Reliable Momentum Entry Alerts - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):